lifestyle.ucconnection.org

Author: Connect Biopharma Holdings Limited

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

April 26, 2026
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

April 1, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing

March 30, 2026
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

March 30, 2026
Connect Biopharma Announces $20.2 Million Private Placement Financing

March 30, 2026
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

March 30, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2026
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 10, 2026
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

March 3, 2026
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026